Y. Merrouche

发表

Recommendations for a lifestyle which could prevent breast cancer and its relapse: physical activity and dietetic aspects.

N. Magné, Cyrus Chargari, F. Chauvin, 2011, Critical reviews in oncology/hematology.

Pharmacogenetic tailoring of irinotecan-based first-line chemotherapy in metastatic colorectal cancer: results of a pilot study.

G. Milano, E. Chatelut, J. Delord, 2011, Anticancer research.

A FOCUS ON IL-17 TARGETING TREATMENTS IN PSORIASIS

M. Bagot, A. Bensussan, J. Giustiniani, 2016 .

Identifying the Primary Site Using Gene Expression Profiling in Patients with Carcinoma of an Unknown Primary (CUP): A Feasibility Study from the GEFCAPI

M. Mathieu, Y. Loriot, K. Fizazi, 2012, Oncology Research and Treatment.

Identifying the primary site using gene expression profiling in patients with carcinoma of an unknown primary (CUP): a feasibility study from the GEFCAPI.

M. Mathieu, E. Blot, Y. Loriot, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Radiotherapy for head and neck cancer in nonagenarian patients: a possible cornerstone?

N. Magné, R. Rivoirard, P. Fournel, 2015, European Archives of Oto-Rhino-Laryngology.

From Randomised Clinical Trials to Clinical Practice

Y. Merrouche, M. Woronoff-lemsi, S. Limat, 2012, PharmacoEconomics.

Phase II study assessing lapatinib added to letrozole in patients with progressive disease under aromatase inhibitor in metastatic breast cancer—Study BES 06

G. Romieu, X. Pivot, M. Demarchi, 2013, Targeted Oncology.

Autophagy is decreased in triple-negative breast carcinoma involving likely the MUC1-EGFR-NEU1 signalling pathway.

L. Debelle, F. Antonicelli, C. Garbar, 2015, International journal of clinical and experimental pathology.

Identification of CD245 as myosin 18A, a receptor for surfactant A: A novel pathway for activating human NK lymphocytes

D. Gossot, P. Validire, M. Bagot, 2016, Oncoimmunology.

High-Dose Irinotecan plus LV5FU2 or Simplified LV5FU (HD-FOLFIRI) for Patients with Untreated Metastatic Colorectal Cancer: A New Way to Allow Resection of Liver Metastases?

M. Ducreux, V. Boige, J. Raoul, 2008, Oncology.

Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer.

D. Pezet, J. Raoul, E. Gamelin, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Secondary acute promyelocytic leukemia following irinotecan and oxaliplatin for advanced colon cancer.

F. Mugneret, Y. Merrouche, J. Cahn, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset.

R. Greil, B. Chauffert, S. Barni, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Portrait, treatment choices and management of breast cancer in nonagenarians: an ongoing challenge.

N. Magné, Cyrus Chargari, R. Rivoirard, 2014, Breast.

Translating Clinical Evidence-Based Medicine into the Real World: Single-Center Experience with Cabazitaxel in Metastatic Prostate Cancer Patients

N. Magné, P. Fournel, G. de Laroche, 2016, Chemotherapy.

Phase I study of RP 49532A, a new protein-synthesis inhibitor, in patients with advanced refractory solid tumors

Y. Merrouche, M. Alakl, J. Guastalla, 2004, Cancer Chemotherapy and Pharmacology.

Chemotherapy Regimen in Nonagenarian Cancer Patients: A Bi-Institutional Experience

N. Magné, S. Kullab, R. Rivoirard, 2015, Chemotherapy.

The Importance of Identifying CUP Subsets

N. Pavlidis, Y. Merrouche, 2006 .

Clinical application of retroviral gene transfer in oncology: results of a French study with tumor-infiltrating lymphocytes transduced with the gene of resistance to neomycin.

C. Bain, V. Combaret, R. Moen, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

General management of nonagenarian patients: a review of the literature.

N. Magné, Cyrus Chargari, R. Rivoirard, 2014, Swiss medical weekly.

Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors.

P. Fumoleau, M. Marty, C. Puozzo, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[Standards, Options and Recommendations for the management of patient with carcinoma of unknown primary site].

S. Culine, A. Bataillard, J. Coindre, 2002, Bulletin du cancer.

Clinical application of gene transfer in oncology: preliminary results of a French study

C. Bain, M. Favrot, T. Philip, 1994 .

Absolute bioavailability and pharmacokinetics (PK) of oral vinorelbine (VRL) in patients (pts) with solid tumors

P. Fumoleau, M. Marty, A. Adenis, 1997 .

IL-17E synergizes with EGF and confers in vitro resistance to EGFR-targeted therapies in TNBC cells

F. Antonicelli, C. Garbar, J. Bastid, 2016, Oncotarget.

Subcutaneous low-dose recombinant interleukin 2 and alpha-interferon in patients with metastatic renal cell carcinoma.

J. Blay, A. Ravaud, T. Philip, 1994, British Journal of Cancer.

Interleukin-2 Therapy: Report on 129 Patients and Three Different Schedules

J. Blay, M. Favrot, C. Lasset, 1994 .

One‐year COVID‐19 outcomes on the oncology care patient pathway: Results of a French descriptive, cross‐sectional comprehensive study (ONCOCARE‐COV)

D. Botsen, O. Bouché, F. Slimano, 2022, Cancer medicine.

Addition of oxaliplatin (Eloxatine®, LOHP) to the same leucovorin (LV) and 5 fluorouracil (5FU) bimonthly regimens after progression in patients (pts) with metastatic colorectal cancer (MCRC): Preliminary report

O. Bouché, A. Gramont, T. André, 1997 .

Efficacy of 5FU + cisplatin (FUP) compared to bolus 5FU (FU) in advanced pancreatic carcinoma (APC)

J. Pignon, M. Ychou, M. Ducreux, 1999 .

Dramatic Changes in Oncology Care Pathways During the COVID‐19 Pandemic: The French ONCOCARE‐COV Study

O. Bouché, Y. Merrouche, C. Carlier, 2020, The oncologist.

Estimation of the risk for nutritional state degradation in patients with cancer: development of a screening tool based on results from a cross-sectional survey.

J. Vergnon, F. Chauvin, P. Michaud, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Uterine and Ovary Carcinosarcomas: Outcome, Prognosis Factors, and Adjuvant Therapy

N. Magné, R. Rivoirard, A. Levy, 2015, American journal of clinical oncology.

Correlation between clinical response to interleukin 2 and HLA phenotypes in patients with metastatic renal cell carcinoma.

J. Blay, C. Bain, M. Favrot, 1997, British Journal of Cancer.

B7.1 gene transduction of human renal‐cell‐carcinoma cell lines restores the proliferative response and cytotoxic function of allogeneic T cells

C. Bain, M. Colombo, M. Favrot, 1996, International journal of cancer.

Treatment of interleukin-2-induced thrombocytopenia by intravenous immunoglobulin.

V. Cottin, C. Négrier, T. Philip, 1994, European journal of cancer.

Summary of the Standards, Options and Recommendations for the management of patients with carcinoma of unknown primary site (2002)

S. Culine, A. Bataillard, J. Coindre, 2003, British Journal of Cancer.

Mild dyslipidemia accelerates tumorigenesis through expansion of Ly6Chi monocytes and differentiation to pro-angiogenic myeloid cells

E. Tartour, A. Tedgui, J. Lehmann-Che, 2022, Nature Communications.

Chemotherapy treatment induces an increase of autophagy in the luminal breast cancer cell MCF7, but not in the triple-negative MDA-MB231

C. Garbar, C. Mascaux, A. Bensussan, 2017, Scientific Reports.

Carcinoma of the colon

T. Conroy, P. Rougier, P. Lasser, 2001, British Journal of Cancer.

Multiple Roles of the Interleukin IL-17 Members in Breast Cancer and Beyond

J. Lehmann-Che, A. Bensussan, Y. Merrouche, 2020 .

Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline‐ and/or paclitaxel‐containing regimens

J. Blay, P. Biron, I. Ray-Coquard, 1998, Cancer.

Inflammatory breast cancer outcome with epirubicin‐based induction and maintenance chemotherapy

P. Fumoleau, P. Fargeot, P. Kerbrat, 2006, Cancer.

Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site.

S. Culine, A. Laplanche, A. Kramar, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Improvement of malignant serous effusions diagnosis by quantitative analysis of molecular claudin 4 expression

M. Péoc'h, Y. Merrouche, C. Genin, 2010, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

Clinical and economic impact of epoetin in adjuvant-chemotherapy for breast cancer

X. Pivot, Y. Merrouche, M. Woronoff-lemsi, 2006, Supportive Care in Cancer.

From randomised clinical trials to clinical practice : a pragmatic cost-effectiveness analysis of Paclitaxel in first-line therapy for advanced ovarian cancer.

Y. Merrouche, M. Woronoff-lemsi, S. Limat, 2004, PharmacoEconomics.

Quality of final care for terminal cancer patients in a comprehensive cancer centre from the point of view of patients' families

G. Freyer, Y. Merrouche, P. Rebattu, 1996, Supportive Care in Cancer.

[HBV infection: Screening and treatment for oncology patients].

Y. Merrouche, L. D'alteroche, A. Landau, 2018, Bulletin du cancer.

DEEPTHI. T.V. “METAL CHELATES OF 1,3-DIKETONES STRUCTURALLY RELATED TO CURCUMINOIDS”. THESIS. DEPARTMENT OF CHEMISTRY,SREE NEELAKANTA

C. Walsh, H. Gray, S. Lippard, 2022 .

Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy.

S. Culine, T. Conroy, M. Ychou, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Anti-HIV Activities of Novel Nucleoside Analogues: Acyclic and Tricyclic Base Nucleosides

P. Roques, D. Dormont, Y. Merrouche, 1991 .

Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study--trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01).

P. Petrow, S. Culine, X. Pivot, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Development a nd V alidation o f a P rognostic M odel t o P redict the L ength o f S urvival i n P atients W ith C arcinomas o f a n Unknown P rimary S ite

S. Culine, A. Kramar, K. Fizazi, 2002 .

Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?

S. Culine, X. Pivot, J. Douillard, 2007, British Journal of Cancer.

Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma.

J. Blay, E. Goillot, V. Combaret, 1992, Cancer research.

Triple-negative and HER2-overexpressing breast cancer cell sialylation impacts tumor microenvironment T-lymphocyte subset recruitment: a possible mechanism of tumor escape

C. Garbar, C. Mascaux, A. Bensussan, 2018, Cancer management and research.

Sarcoma of vulva, vagina and ovary.

N. Magné, C. Chauleur, C. Chargari, 2011, Best practice & research. Clinical obstetrics & gynaecology.

Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer.

P. Fumoleau, P. Fargeot, P. Kerbrat, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patients with metastatic renal carcinoma candidate for immunotherapy with cytokines. Analysis of a single institution study on 181 patients.

J. Blay, F. Chauvin, C. Lasset, 1993, British Journal of Cancer.

Can we define the mechanism of antitumor response observed during clinical adoptive immunotherapy?

M. Favrot, Y. Merrouche, S. Négrier, 1997, Journal of the National Cancer Institute.

[Cisplatin or carboplatin, that is the question].

N. Magné, Cyrus Chargari, C. Moncharmont, 2011, Bulletin du cancer.

IL-17A and its homologs IL-25/IL-17E recruit the c-RAF/S6 kinase pathway and the generation of pro-oncogenic LMW-E in breast cancer cells

F. Antonicelli, J. Eliaou, C. Garbar, 2015, Scientific Reports.

Ultraviolet recall dermatitis reaction with sorafenib

N. Magné, Cyrus Chargari, J. Spano, 2011, Investigational new drugs.

[Obesity and cancer].

J. Thariat, Y. Merrouche, S. Vignot, 2017, Bulletin du cancer.

High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancer

M. Ychou, C. Borel, F. Caroli-Bosc, 2002, Cancer Chemotherapy and Pharmacology.

High dose-intensity of irinotecan administered every 3 weeks in advanced cancer patients: a feasibility study.

P. Hérait, J. Armand, M. Marty, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Interleukin-17 Family of Cytokines in Breast Cancer

F. Antonicelli, C. Garbar, A. Bensussan, 2018, International journal of molecular sciences.

Is oral chemotherapy prescription safe for patients? A cross-sectional survey.

N. Magné, F. Chauvin, F. Tinquaut, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Targeting the Tumor Microenvironment: The Protumor Effects of IL-17 Related to Cancer Type

F. Antonicelli, M. Bagot, C. Garbar, 2016, International journal of molecular sciences.

Phase II study of fotemustine as second-line treatment after failure of immunotherapy in metastatic renal cell carcinoma

F. Chauvin, J. Bérille, T. Philip, 2004, Cancer Chemotherapy and Pharmacology.

Adoptive Immunotherapy with Interleukin-2 and LAK Cells or Gene Modified TIL in Patients with Renal Cell Carcinoma: Clinical and Laboratory Data

J. Blay, M. Favrot, T. Philip, 1995 .

Intravenous interleukin-2 in patients over 65 with metastatic renal carcinoma.

J. Blay, P. Thiesse, A. Mercatello, 1992, British Journal of Cancer.

A phase I antiemetic study of MDL 73,147EF, a novel 5-hydroxytryptamine antagonist in cancer patients receiving emetogenic chemotherapy.

Y. Merrouche, P. Rebattu, J. Guastalla, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen.

O. Bouché, A. de Gramont, T. André, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Restriction of the T‐cell repertoire in tumor‐infiltrating lymphocytes from nine patients with renal‐cell carcinoma relevance of the CDR3 length analysis for the identification of in situ clonal T‐cell expansions

C. Bain, P. Kourilsky, J. Even, 1996, International journal of cancer.

Reappraisal of the role of bevacizumab in the therapeutic strategy in advanced renal cell carcinoma.

N. Magné, A. Levy, C. Massard, 2012, Clinical genitourinary cancer.

Hematopoietic growth factors and chemoprotectants: should we move toward a two-step process for phase I clinical trials in oncology?

Y. Merrouche, G. Catimel, M. Clavel, 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

[Periarteritis nodosa related to hepatitis B virus. Determination of a new therapeutic strategy: 13 cases].

L. Guillevin, Y. Merrouche, A. Leon, 1988, Presse medicale.

Delayed care for patients with newly diagnosed cancer due to COVID-19 and estimated impact on cancer mortality in France

T. Conroy, M. Ychou, F. Penault-Llorca, 2021, ESMO Open.

Phase II Trial of Pegylated Liposomal Doxorubicin in Combination With Gemcitabine in Metastatic Breast Cancer Patients

N. Magné, Cyrus Chargari, C. Dumanoir, 2012, American journal of clinical oncology.

Relationship between nutritional status and quality of life in patients with cancer.

M. Vasson, F. Chauvin, P. Michaud, 2008, European journal of cancer.

Improving Adherence to Adjuvant Endocrine Therapy in Breast Cancer Through a Therapeutic Educational Approach: A Feasibility Study .

F. Chauvin, F. Tinquaut, A. Bourmaud, 2016, Oncology nursing forum.

Curative‐Intended Treatment of Squamous Cell Anal Carcinoma in Elderly Adults

N. Magné, Cyrus Chargari, A. Levy, 2012, Journal of the American Geriatrics Society.

Feasibility of radiation therapy in patients 90years of age and older: a French multicentre analysis.

N. Magné, Cyrus Chargari, R. Rivoirard, 2014, European journal of cancer.

Doxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell carcinoma: a phase II study of the Genitourinary Group of the French Federation of Cancer Centers.

S. Culine, J. Droz, B. Escudier, 2002, The Journal of urology.

IL-17 and Triple Negative Breast Cancer

F. Antonicelli, J. Giustiniani, Y. Merrouche, 2016 .

[Use of anti-EGFR antibodies (cetuximab and panitumumab) in the treatment of metastatic colorectal cancer in KRAS wild type patients].

Y. Merrouche, C. Bosacki, D. Smith, 2009, Bulletin du cancer.

POSSIBLE INVOLVEMENT OF HIV IN NEUROPSYCHIATRIC EPISODE IN PATIENT SERONEGATIVE FOR TWO (OR MORE) YEARS

H. Fleury, D. Dormont, P. Brunet, 1987, The Lancet.

Bevacizumab in HIV-positive patients: concerns about safety and potential for therapeutic use

N. Magné, Cyrus Chargari, J. Spano, 2014, Journal of chemotherapy.

[The announcement of the diagnosis of cancer: point of view of the general practitioner].

N. Magné, R. Gonthier, Y. Merrouche, 2013, Bulletin du cancer.

The Multifaceted Immune System

Y. Merrouche, Bensussan, J. Fabre, 2016 .

[Recommendations for clinical practice: management of stomach adenocarcinoma].

M. Ychou, O. Bouché, Y. Merrouche, 2006, Bulletin du Cancer.

Phase III randomized study of two fluorouracil combinations with either interferon alfa-2a or leucovorin for advanced colorectal cancer. Corfu-A Study Group.

G. Batist, T. Shore, F. Porzsolt, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[Immunotherapy of metastatic kidney cancer].

J. Blay, P. Thiesse, T. Philip, 1993, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

Small-cell carcinoma of the esophagus: report of three cases and review of the literature with emphasis on therapy.

J. Bosset, Y. Merrouche, L. Martín, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Chemotherapy treatment induces an increase of autophagy in the luminal breast cancer cell MCF7, but not in the triple-negative MDA-MB231

C. Garbar, C. Mascaux, A. Bensussan, 2017, Scientific Reports.

Intravenous interleukin-2 just after high dose BCNU and autologous bone marrow transplantation. Report of a multicentric French pilot study.

D. Blaise, P. Biron, I. Philip, 1991, Bone marrow transplantation.

Multicentric Phase II Study of Cisplatin and Etoposide in Patients With Metastatic Carcinoma of Unknown Primary

C. Lasset, Y. Merrouche, S. Négrier, 2000, American journal of clinical oncology.

Interleukin 17 in the tumor microenvironment: A potent target for anticancer immunotherapy?

F. Antonicelli, C. Garbar, A. Bensussan, 2017 .

Abstract 3171: IL-25/IL-17E does not induce breast tumor cell apoptosis and both IL-17A and IL-25/IL-17E contribute to breast cancer survival and proliferation associated with generation of pro-oncogenic low molecular forms of cyclin E

J. Eliaou, C. Garbar, N. Bonnefoy, 2015 .